- Home
- NRC vs LRMR Comparison
NRC vs LRMR Comparison
Compare NRC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- LRMR
- Stock Information
- Founded
- NRC 1981
- LRMR N/A
- Country
- NRC United States
- LRMR United States
- Employees
- NRC N/A
- LRMR N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- LRMR Health Care
- Exchange
- NRC Nasdaq
- LRMR Nasdaq
- Market Cap
- NRC 394.2M
- LRMR 426.9M
- IPO Year
- NRC N/A
- LRMR N/A
- Fundamental
- Price
- NRC $15.61
- LRMR $3.19
- Analyst Decision
- NRC
- LRMR Strong Buy
- Analyst Count
- NRC 0
- LRMR 9
- Target Price
- NRC N/A
- LRMR $19.44
- AVG Volume (30 Days)
- NRC 78.5K
- LRMR 639.4K
- Earning Date
- NRC 01-27-2025
- LRMR 03-13-2025
- Dividend Yield
- NRC 3.08%
- LRMR N/A
- EPS Growth
- NRC N/A
- LRMR N/A
- EPS
- NRC 1.04
- LRMR N/A
- Revenue
- NRC $143,060,000.00
- LRMR N/A
- Revenue This Year
- NRC N/A
- LRMR N/A
- Revenue Next Year
- NRC N/A
- LRMR N/A
- P/E Ratio
- NRC $15.01
- LRMR N/A
- Revenue Growth
- NRC N/A
- LRMR N/A
- 52 Week Low
- NRC $15.59
- LRMR $3.01
- 52 Week High
- NRC $42.00
- LRMR $12.91
- Technical
- Relative Strength Index (RSI)
- NRC 35.77
- LRMR 37.56
- Support Level
- NRC $16.92
- LRMR $3.06
- Resistance Level
- NRC $18.41
- LRMR $3.52
- Average True Range (ATR)
- NRC 0.68
- LRMR 0.22
- MACD
- NRC -0.07
- LRMR 0.02
- Stochastic Oscillator
- NRC 0.73
- LRMR 15.66
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.